Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases

Background: Brain radiotherapy is the standard treatment option for multiple brain metastases (BMs) from non-small cell lung cancer (NSCLC), especially in the absence of a driver mutation. However, the prognosis for such patients remains poor. Apatinib is a potent antiangiogenic compound directed at...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Xiaofang, Liu, Huali, Wang, Mingwei, Peng, Min, Ruan, Peng, Verma, Vivek, Han, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174649/
https://www.ncbi.nlm.nih.gov/pubmed/32351894
http://dx.doi.org/10.3389/fonc.2020.00517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174649/
https://www.ncbi.nlm.nih.gov/pubmed/32351894
http://dx.doi.org/10.3389/fonc.2020.00517

Ejemplares similares